EntryPoint Capital LLC Buys 1,892 Shares of Progyny, Inc. (NASDAQ:PGNY)

EntryPoint Capital LLC raised its stake in Progyny, Inc. (NASDAQ:PGNY) by 90.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 3,989 shares of the company’s stock after purchasing an additional 1,892 shares during the quarter. EntryPoint Capital LLC’s holdings in Progyny were worth $152,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its stake in shares of Progyny by 9.3% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock valued at $115,000 after buying an additional 264 shares during the period. Caprock Group LLC increased its stake in shares of Progyny by 5.3% during the first quarter. Caprock Group LLC now owns 6,288 shares of the company’s stock valued at $240,000 after buying an additional 319 shares during the period. M&G Investment Management Ltd. increased its stake in shares of Progyny by 1.2% during the fourth quarter. M&G Investment Management Ltd. now owns 32,980 shares of the company’s stock valued at $1,220,000 after buying an additional 387 shares during the period. FourThought Financial Partners LLC grew its stake in Progyny by 1.3% in the fourth quarter. FourThought Financial Partners LLC now owns 32,683 shares of the company’s stock worth $1,215,000 after purchasing an additional 423 shares during the period. Finally, New York State Teachers Retirement System grew its stake in Progyny by 0.6% in the fourth quarter. New York State Teachers Retirement System now owns 77,434 shares of the company’s stock worth $2,879,000 after purchasing an additional 500 shares during the period. Institutional investors own 94.93% of the company’s stock.

Progyny Trading Up 1.6 %

PGNY stock traded up $0.46 during trading on Friday, reaching $29.06. The stock had a trading volume of 164,282 shares, compared to its average volume of 953,003. Progyny, Inc. has a 52 week low of $23.90 and a 52 week high of $44.95. The stock’s 50 day moving average is $27.60 and its two-hundred day moving average is $33.11. The firm has a market cap of $2.77 billion, a PE ratio of 46.89, a PEG ratio of 1.81 and a beta of 1.46.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, May 9th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The company had revenue of $278.08 million for the quarter, compared to the consensus estimate of $289.41 million. During the same quarter in the prior year, the company earned $0.18 earnings per share. Progyny’s revenue was up 7.6% on a year-over-year basis. On average, research analysts anticipate that Progyny, Inc. will post 0.73 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on PGNY shares. BTIG Research dropped their target price on Progyny from $50.00 to $41.00 and set a “buy” rating on the stock in a report on Friday, May 10th. KeyCorp downgraded Progyny from an “overweight” rating to a “sector weight” rating in a report on Friday, May 10th. Truist Financial dropped their target price on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 17th. Canaccord Genuity Group lowered their price target on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $48.00 price target on shares of Progyny in a report on Thursday, May 16th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.40.

Insider Buying and Selling at Progyny

In other Progyny news, President Michael E. Sturmer sold 4,515 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total value of $144,254.25. Following the transaction, the president now owns 380,038 shares of the company’s stock, valued at $12,142,214.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Progyny news, President Michael E. Sturmer sold 4,515 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total value of $144,254.25. Following the completion of the sale, the president now owns 380,038 shares in the company, valued at $12,142,214.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Michael E. Sturmer sold 9,030 shares of the company’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $30.00, for a total value of $270,900.00. Following the completion of the sale, the president now owns 362,583 shares of the company’s stock, valued at approximately $10,877,490. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,007 shares of company stock valued at $456,660. 12.30% of the stock is owned by company insiders.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.